(Q35544962)

8 August 2017

1 reference

title

Current treatment for Alzheimer disease and future prospects (English)

1 reference

8 August 2017

Current Treatment for Alzheimer Disease and Future Prospects (English)

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

15 March 2024

0 references

Pierre N. Tariot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512816

15 March 2024

Howard J. Federoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512816

15 March 2024

language of work or name

English

0 references

publication date

1 July 2003

1 reference

full work available at URL

8 August 2017

http://journals.lww.com/00002093-200307004-00005

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Alzheimer Disease and Associated Disorders

15 March 2024

published in

1 reference

8 August 2017

volume

17 Suppl 4

1 reference

8 August 2017

page(s)

S105-13

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Amyloidosis and Alzheimer's disease

15 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Alzheimer's disease-do tauists and baptists finally shake hands?

15 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

15 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts

15 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100.

15 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

15 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A potential role for apoptosis in neurodegeneration and Alzheimer's disease

15 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Strategies for drug discovery for cognitive aging and Alzheimer's disease.

15 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets

15 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets

15 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

15 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

15 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

15 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

15 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

15 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

15 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

15 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

15 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

The utility of muscarinic agonists in the treatment of Alzheimer's disease

15 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Delayed neurotoxicity of excitatory amino acids in vitro

15 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.

15 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

15 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

15 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Memantine in moderate-to-severe Alzheimer's disease

15 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

15 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease.

15 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

15 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins: protection by an extract of Ginkgo biloba (EGb 761)

15 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus.

15 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia

15 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type.

15 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.

15 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease

15 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Clinical trial of indomethacin in Alzheimer's disease.

15 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

15 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

15 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

15 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease.

15 March 2024

45

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type.

15 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type).

15 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type

15 March 2024

48

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

High-dose estradiol improves cognition for women with AD: results of a randomized study

15 March 2024

49

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

15 March 2024

50

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Prevention of Alzheimer's disease: where we stand

15 March 2024

51

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

15 March 2024

52

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Gamma-secretase inhibitors and Alzheimer's disease

15 March 2024

53

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Beta-secretase (BACE) as a drug target for Alzheimer's disease

15 March 2024

54

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease

15 March 2024

55

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Nerve inflammation halts trial for Alzheimer's drug.

15 March 2024

56

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion

15 March 2024

57

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales

15 March 2024

58

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

Calpain inhibitors: a treatment for Alzheimer's disease

15 March 2024

59

1 reference

https://api.crossref.org/works/10.1097/00002093-200307004-00005

15 March 2024

Identifiers

1 reference

8 August 2017

1 reference